Biology and toxicology of PPARγ ligands

Human and Experimental Toxicology

Volumn 21, Issue 8, 2002, Pages 429-437

  Tugwood, J D ^a   Montague, C T ^b  

^a ASTRAZENECA   (United Kingdom)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

PPARgamma; Thiazolidinediones; Type II diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; CELL RECEPTOR; DNA BINDING PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGY; BONE MARROW DISEASE; CARDIOTOXICITY; CLINICAL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EDEMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN SENSITIVITY; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; TOXICOLOGY; WEIGHT GAIN; CHEMISTRY; DRUG POTENTIATION; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; MICROBODY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALIA;

DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; LIGANDS; MICROBODIES; NUCLEAR PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRESSOR PROTEINS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 0036667221     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327102ht282oa     Document Type: Article

References (41)

1. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
2. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-56.
3. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883-88.
4. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
5. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-68.
6. Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995; 38: 764-71.
7. Rosenbaum SE, Greenberg AS. The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes. Mol Endocrinol 1998; 12: 1150-60.
8. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997; 272: 10585-93.
9. Pallett AL, Morton NM, Cawthorne MA, Emilsson V. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem Biophys Res Commun 1997; 238: 267-70.
10. Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900-908.
11. Masuda K, Okamoto Y, Tsuura Y, et al. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995; 38: 24-30.
12. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Biochem Biophys Res Commun 1997; 237: 359-61.
13. Kwon G, Xu G, Marshall CA, McDaniel ML. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999; 274: 18702-708.
14. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglita-zone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998; 273: 3547-50.
15. Komers R, Vrana A. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 1998; 47: 215-25.
16. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
17. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-40.
18. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
19. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117: 73-81.
20. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-89.
21. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-56.
22. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-11.
23. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
24. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804.
25. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-57.
26. Breider MA, Gough AW, Haskins JR, et al. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999; 27: 545-52.
27. Pickavance LC, Tadayyon M, Widdowson PS, et al. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Phormacol 1999; 128: 1570-76.
28. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46: 433-39.
29. Ramachandran V, Kostrubsky VE, Komoroski BJ, et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab Dispos 1999; 27: 1194-99.
30. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27-39.
31. Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998; 21: 2140-43.
32. Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Ear J Clin Pharmacol 1998; 54: 567-71.
33. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglita-zone. A case report. Ann Intern Med 2000; 132: 121-24.
34. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305-13.
35. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mal Pharmacol 1996; 50: 1087-94.
36. Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Gell Biochem 1999; 74: 357-71.
37. Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140: 5060-65.
38. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist / antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11: 657-66.
39. Reginato MJ, Bailey ST, Krakow SL, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem 1998; 273: 32679-84.
40. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
41. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-95.